A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

This Phase 1b study is testing a new experimental drug called QX1206 in people with type 2 diabetes who also have non-alcoholic fatty liver disease (NAFLD) — a condition where too much fat builds up in the liver. The study is assessing whether the drug is safe and what dose is appropriate. **You may be eligible if...** - You are between 18 and 64 years old - You have been diagnosed with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) - Your BMI is between 18 and 45 kg/m² - Your blood sugar is not severely uncontrolled (HbA1c below 10.5%) - Your liver enzyme levels and kidney function are within acceptable ranges - You are willing to use contraception if of childbearing potential **You may NOT be eligible if...** - Your diabetes is poorly controlled - You have a serious medical condition limiting daily activities - You drink alcohol heavily - Your liver enzymes are more than 5 times the upper limit of normal - Your triglycerides are very high (above 500 mg/dL) - You take medications that are known to cause fatty liver - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.